Kiniksa Pharmaceuticals
KNSA
266 hedge funds and large institutions have $2.99B invested in Kiniksa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 85 increasing their positions, 82 reducing their positions, and 29 closing their positions.
145% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 29
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
37% more capital invested
Capital invested by funds: $2.18B → $2.99B (+$810M)
17% more funds holding
Funds holding: 228 → 266 (+38)
2.41% more ownership
Funds ownership: 98.95% → 101.36% (+2.4%)
4% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 82
71% less call options, than puts
Call options by funds: $6.04M | Put options by funds: $20.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$117M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$38.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$32.6M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$34.1M |
| 2 |
Millennium Management
New York
|
-$24.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.5M |
| 4 |
D.E. Shaw & Co
New York
|
-$20.2M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$19.9M |
KNSA Hedge Fund Activity: Q2 2026 in Review
266 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2026, worth a combined $2.99B — up 37% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new KNSA positions and 29 closed out — a net gain of 42 holders — while 85 added to existing stakes and 82 trimmed.
The largest buyer was BlackRock, adding an estimated $117M. The largest seller was Acadian Asset Management, cutting an estimated $34.1M.
- 266 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2026, up from 228 in Q1 2026.
- Funds reported $2.99B of Kiniksa Pharmaceuticals stock for Q2 2026, up 37% quarter-over-quarter.
- 71 funds opened new Kiniksa Pharmaceuticals positions in Q2 2026 and 29 closed out, a net change of +42 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $117M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2026 was Acadian Asset Management, an estimated $34.1M sold.
Based on aggregated 13F filings for Q2 2026.